They will use
CEVEC's proprietary CAPGo technology, which is optimal for the production of these otherwise difficult to produce recombinant glycoproteins.
The firms will use
CEVEC's CAPGo technology for the production of recombinant glycoproteins.
2043 Carbosynth LTD 1741 Catalent Pharma Solutions 5031 CellTrend GmbH 4521 Cerbios-Pharma SA 5354 CEVA 3712
CEVEC Pharmaceuticals GmbH 5025 Clarena 5554 Coldstream Laboratories Inc.
The first legal proceedings regarding infringement of the PER.C6 patent were subsequently launched against
CEVEC. A further European Patent was added in January 2005 specifically relating to the application of PER.C6 for vaccines.